Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neuro-Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/neuonc/nou148PMID 25100872PMCID PMC4483051
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811).

  2016cited by this paper
• CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

  2013cited by this paper
• Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein

  2013cited by this paper
• Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

  2013cited by this paper
• Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors

  2013cited by this paper
• Atypical and anaplastic meningiomas treated with bevacizumab

  2012cited by this paper
• Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

  2012cited by this paper
• Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Angiogenesis in meningiomas

  2011cited by this paper
• Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

  2011cited by this paper
• Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

  2011cited by this paper
• Medical therapies for meningiomas

  2010cited by this paper
• A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

  2010cited by this paper
• Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

  2009cited by this paper
• Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

  2009cited by this paper
• Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

  2009cited by this paper
• Advances in meningioma therapy

  2009cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Salvage chemotherapy With CPT-11 for recurrent meningioma

  2006cited by this paper
• Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression

  2006cited by this paper
• A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study

  2005cited by this paper
• Temozolomide for treatment-resistant recurrent meningioma

  2004cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• PDGF receptors as cancer drug targets.

  2003cited by this paper
• Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.

  2001cited by this paper
• Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells.

  2001cited by this paper
• VEGF in Brain Tumors

  2000cited by this paper
• The Treatment of Recurrent Unresectable and Malignant Meningiomas with Interferon Alpha-2B.

  1997cited by this paper
• The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.

  1997cited by this paper
• Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor.

  1996cited by this paper
• Platelet-derived growth factor expression and stimulation in human meningiomas.

  1994cited by this paper
• Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.

  1991cited by this paper
• Response criteria for phase II studies of supratentorial malignant glioma.

  1990cited by this paper
• Expression of PDGF β‐receptors in human meningioma cells

  1990cited by this paper
• Human meningiomas co‐express platelet‐derived growth factor (pdgf) and pdgf‐receptor genes and their protein products

  1990cited by this paper
• Expression of PDGF beta-receptors in human meningioma cells.

  1990cited by this paper
• Antiestrogenic therapy of meningiomas--a pilot study.

  1985cited by this paper

• Peritumoral edema in meningiomas: a review of influencing factors, mechanisms, and management

  2026cites this paper
• Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat.

  2026cites this paper
• Radioligand Therapy in Meningiomas: Today’s Evidence, Tomorrow’s Possibilities

  2026cites this paper
• Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma

  2026cites this paper
• [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data

  2025cites this paper
• Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design.

  2025cites this paper
• A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas

  2025influential citation
• Malignant Meningiomas: From Diagnostics to Treatment

  2025cites this paper
• Meningioma: Novel Diagnostic and Therapeutic Approaches

  2025cites this paper
• Insights into recurrent meningioma: biomarkers and therapeutic strategies

  2025influential citation
• Side effects of boron neutron capture therapy.

  2025cites this paper
• Molecular Profiling of Belumosudil-Treated IOMM-Lee Meningioma Cells Reveals Repurposing Potential via Enhanced Oxidative Phosphorylation and ROS-Mediated Cell Death.

  2025cites this paper
• Insights on Survival and Recurrence After Surgery in Malignant Meningiomas: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Carboplatin–gemcitabine for refractory high‐grade meningiomas: A study from the French national OMEGA consortium

  2025cites this paper
• Gene therapy and nanomedicine for meningioma treatment.

  2025cites this paper
• Emerging targeted therapies in meningiomas.

  2025cites this paper
• Evolving Treatment Paradigms of Meningiomas; a Precision Medicine Perspective

  2025cites this paper
• A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

  2025cites this paper
• Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors.

  2025cites this paper
• New Targets, New Agents, and Radiotherapy: Primary Brain Tumors

  2025cites this paper
• SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors

  2025cites this paper
• A novel compound, SYHA1813, inhibits malignant meningioma growth directly by boosting p53 pathway activation and impairing DNA repair

  2025cites this paper
• Case report: Clonal evolution analysis of a rare case of meningioma lung metastases identifies actionable alterations in matched longitudinal tumour samples

  2025cites this paper
• Unmasking benign intradural-extramedullary spinal tumors: a systematic review on treatment outcomes and radiological features

  2025cites this paper
• Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)

  2025influential citation
• The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas

  2024cites this paper
• A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor

  2024cites this paper
• Impact on natural history of atypical meningioma after changes in 2016 edition of the world health organization (WHO) classification of central nervous system tumors: a literature review

  2024influential citation
• Related mechanisms, current treatments, and new perspectives in meningioma

  2024cites this paper
• Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

  2024cites this paper
• Spinal Meningiomas: A Comprehensive Review and Update on Advancements in Molecular Characterization, Diagnostics, Surgical Approach and Technology, and Alternative Therapies

  2024cites this paper
• Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma

  2024cites this paper
• Molecular developments in parasellar tumors and potential therapeutic implications.

  2024cites this paper
• Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients

  2024cites this paper
• European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection

  2024cites this paper
• The current status and future perspectives of clinical boron neutron capture therapy trials

  2024cites this paper
• Chemotherapy in the structure of complex treatment of patients with recurrent intracranial meningiomas

  2024cites this paper
• Management Approaches in WHO Grade III Meningioma: A National Oncology Trainees' Collaborative for Healthcare Research (NOTCH) UK Multi-Centre Retrospective Study.

  2024cites this paper
• The role of radiation therapy and systemic treatments in meningioma: The present and the future

  2023cites this paper
• Hemangiopericytoma of the skull base: A long-term complete response with trimodality treatment.

  2023cites this paper
• Case Report: Recurrent meningioma with multiple metastases

  2023cites this paper
• Clinical features and surgical outcomes of primary spinal anaplastic meningioma: a cases series and literature review

  2023cites this paper
• Medical Management of Meningiomas.

  2023cites this paper
• Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.

  2023cites this paper
• Ways to personalize the treatment of patients with relapse and continued growth of intracranial meningiomas

  2023cites this paper
• Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression

  2023cites this paper
• Advances and trends in meningioma research over the last decade: A scientometric and visual analysis

  2023cites this paper
• Innovative treatments for meningiomas.

  2023cites this paper
• Management of Atypical and Anaplastic Meningiomas.

  2023cites this paper
• Meningioma and Other Meningeal Tumors.

  2023cites this paper
• Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors

  2023cites this paper
• Hotspots and Trends of Meningiomas Research based on Bibliometrics from 2011-2021.

  2023cites this paper
• Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review

  2023cites this paper
• Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center

  2023cites this paper
• Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications

  2023cites this paper
• Intracranial meningiomas: an update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy

  2023cites this paper
• Case report and literature review: exploration of molecular therapeutic targets in recurrent malignant meningioma through comprehensive genetic analysis with Todai OncoPanel

  2023cites this paper
• Advances in the systemic therapy for recurrent meningiomas and the challenges ahead

  2023cites this paper
• Novel Systemic Approaches for the Management of Meningiomas: Immunotherapy and Targeted Therapies.

  2023cites this paper
• Signaling pathways in brain tumors and therapeutic interventions

  2023cites this paper
• Recurrent Meningothelial Meningioma With Multiple Extensions: A Complex Case Study

  2023cites this paper
• Interdisciplinary Therapeutic Approaches to Atypical and Malignant Meningiomas

  2023cites this paper
• The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review

  2023influential citation
• Malignant anaplastic meningioma in neurofibromatosis type 1 patient: a rare case report

  2022cites this paper
• Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib

  2022cites this paper
• The role of bevacizumab for treatment-refractory intracranial meningiomas: a single institution’s experience and a systematic review of the literature

  2022cites this paper
• Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3

  2022cites this paper
• Intracranial meningiomas: clinical, intrascopic and pathomorphological causes of recurrence (literature review)

  2022cites this paper
• A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma

  2022cites this paper
• Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)

  2022cites this paper
• Management of Recurrent Meningiomas: State of the Art and Perspectives

  2022cites this paper
• Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?

  2022cites this paper
• Postoperative radiotherapy for meningiomas – a decision-making analysis

  2022cites this paper
• Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review

  2022cites this paper
• [Targeted Drug Therapy for Intracranial Tumors].

  2022cites this paper
• Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins

  2022cites this paper
• Identification and Management of Aggressive Meningiomas

  2022cites this paper
• Malignant meningioma

  2022cites this paper
• Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado

  2022cites this paper
• Emerging systemic treatment options in meningioma

  2022cites this paper
• How useful is chemotherapy for atypical and anaplastic meningiomas?

  2022cites this paper
• Cancer treatment and drug-induced QT interval prolongation: A review

  2022cites this paper
• Biology and Treatment of Meningiomas: A Reappraisal.

  2022cites this paper
• Pharmacological Landscape of FDA-approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas.

  2022cites this paper
• Clinical factors and outcomes of malignant meningioma: a population-based study

  2022cites this paper
• Negative Impact of COVID-19 Upon Primary Brain Tumor Care

  2021cites this paper
• Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

  2021cites this paper
• Foundations of Neuro-Oncology: A Multidisciplinary Approach.

  2021cites this paper
• Systemic Treatments for Grade II and III Meningiomas (WHO)

  2021cites this paper
• Bioinformatic analyses determine the importance of CXCL2 and CXCL8 in atypical meningioma development and reoccurrence.

  2021cites this paper
• Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients

  2021cites this paper
• Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options

  2021cites this paper
• Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers in Meningioma

  2021cites this paper
• Meningioma genomics: a therapeutic challenge for clinicians.

  2021cites this paper
• Chemotherapy and targeted therapies for meningiomas: what is the evidence?

  2021cites this paper
• Low-grade intracranial meningioma with bilateral pulmonary metastases incidentally detected postpartum: a case report and review of the literature

  2021cites this paper
• Case Report: Identification of a Novel GNAS Mutation and 1p/22q Co-Deletion in a Patient With Multiple Recurrent Meningiomas Sensitive to Sunitinib

  2021influential citation
• Meningioma Surgery in Patients ≥70 Years of Age: Clinical Outcome and Validation of the SKALE Score

  2021cites this paper
• Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets

  2021cites this paper
• Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas

  2021cites this paper